Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The purpose of the present study was to evaluate clinicopathological characteristics, patterns of recurrence, survival outcomes, and implications for the addition of chemoradiotherapy for patients with resected perihilar and intrahepatic cholangiocarcinoma (CCA).

Materials And Methods: For the present retrospective study, we identified 38 and 10 patients with resected perihilar and intrahepatic CCA. In perihilar CCA, adjuvant treatment was given as chemotherapy ( = 13) or chemoradiotherapy ( = 10). In intrahepatic CCA, neoadjuvant treatment was given with transarterial chemoembolization (TACE, = 1) or chemotherapy plus stereotactic body radiation therapy (SBRT, = 1), and adjuvant treatment was given to 7 patients with chemotherapy or chemoradiotherapy.

Results: In perihilar CCA, preoperative biliary drainage procedures were performed in 27 out of 30 patients with jaundice. The adjacent liver showed secondary sclerosing cholangitis ( = 5) and fibrosis ( = 19). Locoregional recurrence involved the hepaticojejunostomy anastomotic site and lymph nodes. In intrahepatic CCA, the adjacent liver revealed cirrhosis ( = 1), secondary sclerosing cholangitis ( = 1), and fibrosis ( = 6). The sites of recurrence were in the remnant liver and lymph nodes ( = 6). In perihilar CCA, the median overall survival (OS) and disease-free survival (DFS) rates were 30.1 months (95% CI: 22.9-37.4) and 15.1 months (95% CI: 9.74-20.5), respectively. The 2-year and 3-year OS were 60.5% and 44.7%, respectively. Multivariate analysis revealed a significant association of no adjuvant treatment with decreased DFS ( = 0.004), HR 4.03 (95% CI: 1.57-10.4). Recurrence showed an unfavorable association with OS ( = 0.056), HR 2.90 (95% CI: 0.98-8.66). In intrahepatic CCA, the median OS and DFS rates were 41.2 months (95% CI: 13.5-68.9) and 10.8 months (95% CI: 1.98-19.6), respectively. The 2-year and 3-year OS were 66.7% and 53.3%, respectively. The patient with multiple intrahepatic CCA lesions and treated with neoadjuvant chemotherapy and SBRT showed partial pathological necrosis after resection and was disease-free at 3.5 years.

Conclusions: The present study showed the effectiveness of the combination of chemoradiotherapy with resection in improving locoregional disease control and survival in patients with perihilar and intrahepatic CCA.

How To Cite This Article: Sahai P, Rastogi A, Gupta A, Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy. Euroasian J Hepato-Gastroenterol 2024;14(2):134-144.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714106PMC
http://dx.doi.org/10.5005/jp-journals-10018-1440DOI Listing

Publication Analysis

Top Keywords

perihilar intrahepatic
20
intrahepatic cca
20
months 95%
16
intrahepatic cholangiocarcinoma
12
clinicopathological characteristics
12
outcomes implications
12
implications addition
12
addition chemoradiotherapy
12
perihilar cca
12
adjuvant treatment
12

Similar Publications

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.

Lancet Oncol

August 2025

Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Electro

Background: The optimal conversion regimen that allows more patients with unresectable biliary tract cancer to access surgery remains unclear; there is currently no standard conversion therapy for biliary tract cancer in China, with commonly used regimens including immunotherapy-based combinations and local therapy. The ZSAB-TransGOLP study aimed to assess the efficacy and safety of tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in patients with this disease.

Methods: This single-arm, phase 2 study was conducted at two centres in China.

View Article and Find Full Text PDF

Objective: This study explored the feasibility of preoperatively predicting perineural invasion (PNI) of intrahepatic cholangiocarcinoma (ICC) through machine learning based on clinical and CT image features, which may help in individualized clinical decision making and modification of further treatment strategies.

Materials And Methods: This study enrolled 199 patients with histologically confirmed ICC from three institutions for final analysis. 111 patients from Institution I were recruited as the training cohort and internal validation cohort.

View Article and Find Full Text PDF

Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.

View Article and Find Full Text PDF

: The TOPAZ-1 phase III trial reported a survival benefit of using durvalumab, an anti-programmed death ligand 1 (anti-PD-L1) antibody, in combination with gemcitabine and cisplatin (GCD) treatment in patients with advanced biliary tract cancer. This retrospective study investigated the efficacy and safety of GCD treatment for advanced biliary tract cancer in real-world conditions. : The study subjects were 52 patients with biliary tract cancer who received GCD therapy between January 2023 and May 2024.

View Article and Find Full Text PDF

[Cholangiocarcinoma : Histopathological diagnosis, classification and molecular diagnostics-an update].

Pathologie (Heidelb)

August 2025

Institut für Pathologie, RKH Klinikum Ludwigsburg, Lehrkrankenhaus der Medizinischen Fakultät, Universität Heidelberg, Posilipostraße 4, 71640, Ludwigsburg, Deutschland.

The term cholangiocarcinoma covers various malignant epithelial neoplasms with biliary differentiation. The aim of this article is to provide an update with new findings and developments on the etiology, pathogenesis, diagnosis, classification, and molecular diagnostics of intra- and extrahepatic cholangiocarcinomas based on the last review published in this journal in 2020. The basis is the currently available specialist literature, lectures, and discussions at congresses as well as our own findings.

View Article and Find Full Text PDF